We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Apnimed has raised $25m in a Series B financing round to advance its oral disease-modifying therapeutic AD109 for obstructive sleep apnea (OSA) and support its ongoing development and commercialisation plans.
Apnimed announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.